Article Text

PDF
AB1064 Evaluation of Safety Skills of Biotherapies in Tunisia
  1. I. Henchiri,
  2. K. Ben Abdelghani,
  3. A. Fazaa,
  4. S. Kassab,
  5. A. Laatar,
  6. L. Zakraoui
  1. rhumatology, mongi slim hospital, Tunis, Tunisia

Abstract

Background Biotherapies have become common practice in Tunisia, however, they present specific risks that patients must know and learn to manage. So far, patients' security skills have not been studied in our country.

Objectives The present work aims to assess the skills level of patients using biotherapies, in order to improve them.

Methods Patients with chronic arthritis were recuited. we have established a questionnaire with practical situations in which the patient is confronted, based on the biosecure questionnaire. the main items were the leading symptoms to consult, vaccination, contraception, and situations excluding biotherapy.

Results Thirty nine patients were recuited for the study, 77% with SA and 23% with RA. The mean age was 52, and 54% were female. 48% of patients have high education level. Etanercep was used in 15 cases, adalimumab in 12 cases, infleximab in 9 cases and one patient used tocilizumab. The mean duration of biotherapy was four years. 38% were in clinical remission. 69% had already received therapeutic education session about security of biotherapy use, by a doctor in 77% of cases. The median score of the questionnaire was 71,4% (58,8–100%). skills on symptoms must lead to consult and contraception are the least mastered.

Conclusions This work showed that all patients didn't master all situations concerning biotherpy. However, it is important for patients to have a basic control, to minimize the incidence of severe and avoidable side effects such as severe infections.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.